Jul 2026· Cardiovascular Research· Vol 122, pp. 1705-1723· 0 citations
Medicine
TL;DR
Findings unveil the importance of CARDINAL as a key lncRNA regulator of VSMC phenotype alteration and highlight its potential as an RNA target for therapeutic application in vascular diseases.
Abstract
Aims
The phenotype alteration of vascular smooth muscle cells (VSMCs) is critical for vascular physiology and pathology. Transcription factors (TFs) and long non-coding RNAs (lncRNAs) play pivotal roles in the gene regulatory network underlying various biological processes, including the pathogenesis of vascular diseases. Despite the established role of MYOCD as a master TF in VSMC biology, the MYOCD-mediated lncRNA-protein regulatory network in VSMC phenotype alteration remains elusive. Here, we explored long non-coding RNAs (lncRNAs) potentially involved in MYOCD-dependent VSMC regulation.
Methods
AND
Results
We conducted an unbiased screening to identify key lncRNA regulators in this regulatory network using expression correlation analysis in diseased human arteries. As a result, we found that CARDINAL, a VSMC-enriched lncRNA located upstream of MYOCD, exhibiting a strong positive expression correlation with MYOCD. Decreased CARDINAL expression was observed in atherosclerosis in both human and mouse models. Loss of CARDINAL induced phenotypic modulation in human VSMCs and promoted injury-induced neointima formation in mice. Gain-of-function of CARDINAL drove human VSMCs towards a contractile phenotype by activating MYOCD expression in a cis-regulatory manner. Mechanistically, CARDINAL recruited the ATAC histone acetyltransferase complex to the MYOCD promoter by interacting with the histone reader ZZZ3. Subsequently, the complex increased histone acetylation at H3K4 and H3K9, thus activating the MYOCD promoter. Consequently, CARDINAL upregulated the expression of MYOCD and downstream contractile-related genes.
Conclusion
These findings unveil the importance of CARDINAL as a key lncRNA regulator of VSMC phenotype alteration and highlight its potential as an RNA target for therapeutic application in vascular diseases.
Background/Objectives: Papillary thyroid cancer (PTC) is the most common endocrine malignancy and is generally associated with favorable clinical outcomes. However, a subset of tumors develops aggressive phenotypes characterized by increased proliferation, migration, therapeutic resistance, and disease progression. Lon...
D. Quaranto, N. DeSouza, Michelle Carnazza et al.· Genes· 0 citations
BACKGROUND
TIE1 is an endothelial receptor tyrosine kinase, which plays a crucial role in vascular development and remodeling, including in diseases such as diabetic retinopathy (DR). However, the molecular mechanisms and regulatory interactome governing TIE1 function remain largely unknown. Long noncoding RNAs (lncRNA...
Non-coding RNAs play critical roles in regulating gene expression and diverse biological processes. While the roles of microRNAs (miRNAs/miRs) are well known, the roles of long non-coding RNAs (lncRNAs; >200 nucleotides, with little or no protein-coding potential) remain less defined. In this study, we investigated...
Samuel William, Olga A. Postnikova, Sheetal Uppal et al.· Scientific Reports· 0 citations
Among the tens of thousands of annotated long noncoding RNAs (lncRNAs) in the human genome, only a small fraction have been functionally characterized. Here, we show that a well-established inflammatory bowel disease (IBD) risk locus encoded a conserved lncRNA, lnc15 (2310015A10Rik/ENSMUSG00000097729), whose structure...
Ruxiao Yang-Fischer, A. Shearer, Jingyao Zhao et al.· Immunity· 0 citations
A mechanism wherein SChLAP1 modulates AR signaling to promote PCa growth and progression is suggested, suggesting its molecular mechanism and potential to be used as a therapeutic target or biomarker.
The studies reviewed here suggest that TUG1 operates at the crossroads of metabolic and cancer signaling pathways and, therefore, could be considered as a variable for the translational studies, and might be used as a marker and target for cancer diagnosis or therapy.
H. Y. Lafta, Hossein Fallahi, M. Sabbah et al.· Genetics and Molecular Resea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.